Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today

TEMPE, Ariz., Feb. 10, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 clinical trial in dermal scarring.
MORE ON THIS TOPIC